Fig. 1.

IV administration of anti-BMP-2/4 mAb ameliorates the clinical signs of R-EAE. Average clinical scores of R-EAE-induced mice that were IV injected, on day 9 p.i., with 30 μg/mouse of either anti-human BMP-2/4 mAb or the corresponding IC (IgG1) or with PBS, which served as the vehicle control group. The minimum number of mice, after sacrifice for pathological assessment, was 12 mice/group. Anti-BMP-2/4 mAb-treated mice exhibited a significant improvement in EAE scores, compared to the IgG1-treated mice, on days 21–27 (P < 0.03, Mann–Whitney U test), days 29–32 (P < 0.03), and days 38–40 (P < 0.04), and compared to the vehicle (PBS)-treated mice, on days 21–27 (P < 0.04), days 30–32 (P < 0.03), days 34–35 (P < 0.03), and days 38–41 (P ≤ 0.01)